Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease

Ioan-Andrei Iliuta¹, Xuewen Song¹, Lauren Pickel²,³, Amirreza Haghighi¹,⁴, Ravi Retnakaran⁵, James Scholey¹, Hoon-Ki Sung²,³, Gregory R. Steinberg⁶ and York Pei¹*

¹Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada, ²Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁴Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States, ⁵Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Department of Medicine, Centre for Metabolism, Obesity, and Diabetes Research, McMaster University, Hamilton, ON, Canada

Autosomal dominant polycystic kidney disease (ADPKD) is the most common Mendelian kidney disease, affecting approximately one in 1,000 births and accounting for 5% of end-stage kidney disease in developed countries. The pathophysiology of ADPKD is strongly linked to metabolic dysregulation, which may be secondary to defective polycystin function. Overweight and obesity are highly prevalent in patients with ADPKD and constitute an independent risk factor for progression. Recent studies have highlighted reduced AMP-activated protein kinase (AMPK) activity, increased mammalian target of rapamycin (mTOR) signaling, and mitochondrial dysfunction as shared pathobiology between ADPKD and overweight/obesity. Notably, mTOR and AMPK are two diametrically opposed sensors of energy metabolism that regulate cell growth and proliferation. However, treatment with the current generation of mTOR inhibitors is poorly tolerated due to their toxicity, making clinical translation difficult. By contrast, multiple preclinical and clinical studies have shown that pharmacological activation of AMPK provides a promising approach to treat ADPKD. In this narrative review, we summarize the pleiotropic functions of AMPK as a regulator of cellular proliferation, macromolecule metabolism, and mitochondrial biogenesis, and discuss the potential for pharmacological activation of AMPK to treat ADPKD and obesity-related kidney disease.

KEYWORDS
autosomal dominant polycystic kidney disease, energy metabolism, obesity, metabolic dysregulation, AMPK
Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is the most common Mendelian kidney disease (lifetime prevalence of at least 1:1,000 births), accounting for almost 5% of all end-stage kidney disease (ESKD) in developed countries (Harris and Torres, 2009; Menezes and Germino, 2008; Harris and Torres, 2009). Currently, only tolvaptan, an antagonist of vasopressin V2 receptors is approved to treat ADPKD (Irazabal et al., 2011; Torres et al., 2012; Torres et al., 2017). However, tolvaptan is an expensive drug with serious side effects such as significant polyuria, nocturia, and potential liver toxicity (Irazabal et al., 2011). Hence, there is a pressing need for novel interventions that are safe and effective for patients with ADPKD.

The kidneys are among the most metabolically active organs in the body; although they only represent 0.5% of the human body mass, they consume 10% of the body’s oxygen (Nowak and Hopp, 2020). Consequently, the modulation of key metabolic pathways has generated much interest in the field of ADPKD. The pathophysiology of ADPKD was shown to be strongly linked to metabolic dysregulation, which may occur secondary to defective polycystin function (Distefano et al., 2009; Zheng et al., 2009). Metabolic reprogramming, mediated through novel or repurposed drugs, or through dietary changes (e.g., caloric restriction), holds the promise of improving the course of cystic disease (Nowak and Hopp, 2020; Menezes and Germino, 2019; Podrini et al., 2020; Haumann et al., 2020; Pickel et al., 2019; Warner et al., 2016). Recently, overweight and obesity were demonstrated to be independent predictors of ADPKD progression (Nowak et al., 2018; Nowak et al., 2021). This suggests that weight loss could provide a strategy for controlling cyst growth. In this narrative review, we highlight the shared pathobiology between ADPKD and overweight/obesity. In particular, we focus on the interaction between ADPKD and improve obesity-related kidney disease.

Obesity is clinically associated with more severe autosomal dominant polycystic kidney disease

The World Health Organization (WHO) defines overweight and obesity in adults as a body mass index (BMI) ≥25 kg/m² and ≥30 kg/m², respectively. The global prevalence of obesity in adults was 13% in 2016 (15% of women and 11% of men), a threefold increase since 1975 (https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight, updated 9 June 2021). Worryingly, between 1975 and 2016, the global prevalence of obesity in children and adolescents also increased from 0.7 to 5.6% in girls and from 0.9 to 7.8% in boys (Abarca-Gómez et al., 2017). The rate of increase in BMI since 2000 has slowed down in high-income countries, but has accelerated in some regions of the developing world (NCD Risk Factor Collaboration, 2016). Epidemiologic studies have highlighted high BMI as a risk factor for numerous chronic conditions, including cardiovascular disease, diabetes mellitus, chronic kidney disease (CKD), cancer, and musculoskeletal disorders (The GBD 2015 Obesity Collaborators Ashtian Afshin et al., 2017). Obesity results from energy intake exceeding energy expenditure, which leads to adipose tissue expansion (Rosen and Spiegelman, 2006). Contributors to this energy imbalance are numerous, including genetic, epigenetic, physiological, environmental, sociocultural, and behavioral factors (Fall et al., 2017; Gaddé et al., 2018).

Although it was noted almost 20 years ago that the number of patients with ADPKD and concomitant obesity has been increasing, only recently has the impact of high BMI on ADPKD been explored (Schrier et al., 2003). Nowak et al. (2018) observed that, in 441 non-diabetic subjects with early-stage ADPKD, more than half of the cohort was overweight or obese. Importantly, BMI was independently associated with a greater annual percent change in total kidney volume (TKV). Obesity, compared to normal weight, was also independently associated with impairments in kidney function at high risk of rapid progression from the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial (Nowak et al., 2021).

Obesity commonly co-occurs with the metabolic syndrome. The latter is characterized by a cluster of cardiometabolic risk factors including abdominal obesity, high blood pressure, elevated fasting blood glucose, and dyslipidemia (i.e., high triglycerides and low HDL cholesterol) (Alberti et al., 2009). Pietrzak-Nowacka et al. (2009) found that hypertension was the main component of the metabolic syndrome to correlate with ADPKD, whereas BMI and waist-to-hip ratio did not differ compared to age- and gender-matched controls. Fasting glucose levels were higher in patients with ADPKD, but the difference in blood glucose did not persist after an oral glucose tolerance test. However, these findings must be interpreted with caution,
as BMI was not adjusted for kidney and liver volume. Reed et al. (2012) described larger kidney volumes in patients with ADPKD and type 2 diabetes, compared to those with ADPKD alone. However, since BMI was higher on average in the group with type 2 diabetes, it remains unclear whether it was the dysglycemia or elevated BMI that contributed to the results.

Several signaling pathways relevant to obesity, such as AMPK, are also known to play a major role in the pathobiology of ADPKD. The correlation between BMI and cystic disease progression may be explained by a number of mechanisms including metabolic dysregulation related to nutrient availability, hormonal changes such as hyperinsulinemia, low-grade chronic inflammation, or any combination thereof. Examining the pathways common to both obesity and ADPKD may help generate hypotheses to support future mechanistic studies (Nowak et al., 2018).

mTORC1 plays a major role in the pathophysiology of autosomal dominant polycystic kidney disease

The mTOR protein is a serine/threonine kinase central to two different complexes: mTOR complex 1 (mTORC1), which includes six protein components, and mTOR complex 2 (mTORC2), which includes seven. mTORC1 responds to available amino acids and oxygen, growth factors, DNA homeostasis, and cellular energy levels to activate cell proliferation by enhancing protein synthesis, stimulating the cell cycle, and inhibiting autophagy. On the other hand, mTORC2 is involved in the organization of the actin cytoskeleton and regulates mTORC1 function (Laplante and Sabatini, 2012; Yoon, 2017; Boutouja et al., 2019). mTORC1 is downregulated by AMPK, which phosphorylates and inactivates the Raptor component of the complex, and phosphorylates and activates tuberous sclerosis complex 2 (TSC2), a negative regulator upstream of mTORC1 (Figure 1). (Boutouja et al., 2019) mTORC1 signaling promotes protein synthesis by phosphorylating the translational regulators S6 kinase 1 (S6K1) and 4E-binding protein 1 (4E-BP1) (Laplante and Sabatini, 2012). Moreover, mTORC1 is a potent suppressor of autophagy via phosphorylation and inhibition of unc-51-like kinase 1 (ULK1) (Laplante and Sabatini, 2012). mTORC1 is activated in the kidney proximal tubules of obese mice fed a high-fat diet (HFD), and long-term lipid overload was recently shown to induce lysosomal dysfunction, impaired autophagy, and susceptibility to kidney injury (Yamahara et al., 2013; Yamamoto et al., 2017). Enhanced mTORC1 signaling was repeatedly confirmed in the epithelium of kidney cysts, stimulating cell proliferation and inhibiting autophagy, which are both involved in the pathogenesis of ADPKD; multiple preclinical studies of mTORC1 inhibitors sirolimus (rapamycin) and everolimus showed some benefit in rodent models (Table 1). (Tao et al., 2005; Shillingford et al., 2006; Wahl et al., 2006; Wu et al., 2007; Zafar et al., 2009; Shillingford et al., 2010; Zafar et al., 2010; Song et al., 2020)

Interestingly, mTORC1 signaling also stimulates aerobic glycolysis, also known as the Warburg effect, by enhancing the translation of critical mediators such as c-Myc and hypoxia-inducible factor 1α (HIF-1α), which upregulate many glycolytic genes (Figure 1). (Osthus et al., 2000; Thomas et al., 2006; Lee et al., 2020) Aerobic glycolysis refers to the predominant cellular use of glycolysis to generate ATP, as opposed to the more metabolically efficient oxidative phosphorylation, even in the presence of abundant oxygen
(Vander Heiden et al., 2009). Aerobic glycolysis is an important metabolic feature of proliferating cells (such as cancer cells) that facilitates replication of the cellular biomass (nucleotides, amino acids, and lipids) by providing specific molecular components (e.g., reduced nicotinamide adenine dinucleotide phosphate or NADPH) (Vander Heiden et al., 2009). Importantly, the Warburg effect is also a feature of cystic epithelia in ADPKD. Studies in rodents and minipigs showed that inhibiting glycolysis with 2-deoxy-D-glucose (2DG) improved cystic disease (Table 1) (Rowe et al., 2013; Rowe and Boletta, 2014; Chiaravalli et al., 2016; Lian et al., 2019).

However, in studies of patients with ADPKD, treatment with sirolimus and everolimus has produced disappointing results (Table 2). In randomized controlled trials of either sirolimus or everolimus, beneficial effects on TKV were short-lived or confounded by flaws in study design (e.g., small sample size or short follow-up) (Perico et al., 2010; Serra et al., 2010; Walz et al., 2010; Ruggenenti et al., 2016). In two of these studies, side effects from sirolimus prompted investigators to reduce the delivered doses below those intended, therefore potentially jeopardizing the effectiveness of the drug (Perico et al., 2010; Serra et al., 2010). A sirolimus trial including patients with advanced CKD was terminated after 1 year due to accelerated disease progression and multiple side effects (Perico et al., 2010; Serra et al., 2010; Walz et al., 2010; Ruggenenti et al., 2016). In conclusion, pharmacological inhibition of mTORC1 at present is not a promising clinical option for the treatment of ADPKD.

### TABLE 1 In vitro and animal studies investigating metabolic agents of interest in the treatment of ADPKD.

| Agent       | Mechanism of action | Study                                                                 | Experimental model                                                                 | Evidence                                                                 |
|-------------|----------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Sirolimus   | mTOR inhibitor       | Riwanto et al. (2016)                                                 | Human ADPKD cells                                                                 | mRNA expression of glycolytic genes and lactate                          |
|             |                      | Tao et al. (2005)                                                     | Han-SPRD rat                                                                      | Cyst burden, kidney function                                             |
|             |                      | Wahl et al. (2006)                                                   | Han-SPRD rat                                                                      | Cyst burden, kidney function                                             |
|             |                      | Shillingford et al. (2006)                                           | Han-SPRD rat                                                                      | Cyst burden, kidney function                                             |
|             |                      | Zafrar et al. (2009)                                                 | Han-SPRD rat                                                                      | Cyst burden, kidney function                                             |
|             |                      | Zafar et al. (2010)                                                 | Han-SPRD rat                                                                      | Cyst burden, kidney function                                             |
|             |                      | Shillingford et al. (2010)                                           | Han-SPRD rat                                                                      | Cyst burden, kidney function                                             |
| Everolimus  | mTOR inhibitor       | Wu et al. (2007)                                                     | Human ADPKD cells                                                                 | Cyst burden, kidney function                                             |
|             |                      | 2DG Glycolysis inhibitor/AMPK agonant                               | Han-SPRD rat                                                                      | Cyst burden, kidney function                                             |
|             |                      | Rowe et al. (2013)                                                  | • Pkd1fl/fl::Ksp-Cre mouse; Pkd1fl/fl::Ksp-Cre mouse (inactivation of Pkd1 at two time points) | Cyst burden, kidney function                                             |
|             |                      | Riwanto et al. (2016)                                               | • Pkd1fl/fl::Ksp-Cre mouse; Pkd1fl/fl::Ksp-Cre mouse (inactivation of Pkd1 at two time points) | Cyst burden, kidney function                                             |
|             |                      | Liang et al. (2019)                                                 | • Inducible deletion of PKD1 in minipig                                            | Cyst burden, kidney function                                             |
|             |                      | Chang et al. (2017)                                                 | • Morpholino knock-down of pkd2 in zebrafish embryo                               | Cyst burden, kidney function                                             |
|             |                      | Pastor-Soler et al. (2022)                                          | • Homozygous R2377C point mutation in mouse Pkd1                                   | Cyst burden, kidney function                                             |
| Metformin   | AMPK agonist         | Riwanto et al. (2016)                                               | Human ADPKD cells                                                                 | mRNA expression of glycolytic genes and lactate                          |
|             |                      | Takiar et al. (2011)                                                | • MDCK cells cultured with forskolin/IBMX                                          | Cyst size                                                                |
|             |                      | • Embryonic C57/B6 mouse kidneys cultured with cAMP                 | Cyst area                                                                         |                                                                          |
|             |                      | • Pkd1fl/fl::Ksp-Cre mouse                                            | Cyst burden                                                                        |                                                                          |
|             |                      | • Pkd1fl/fl::Ksp-Cre mouse                                            | Cyst burden                                                                        |                                                                          |
|             |                      | • Pkd1fl/fl::Ksp-Cre mouse                                            | Cyst burden                                                                        |                                                                          |
|             |                      | Liang et al. (2019)                                                 | • Inducible deletion of PKD1 in minipig                                            | Cyst burden, kidney function                                             |
|             |                      | Chang et al. (2017)                                                 | • Inducible deletion of PKD1 in minipig                                            | Cyst burden, kidney function                                             |
|             |                      | Pastor-Soler et al. (2022)                                          | • Homozygous R2377C point mutation in mouse Pkd1                                   | Cyst burden, kidney function                                             |
| Salsalate   | AMPK agonist         | Leonhard et al. (2019)                                              | • iKsp-Pkd2 fl/fl conditional knock-out mouse                                      | Cyst burden, kidney function                                             |
| Fenofibrate | PPARa agonist        | Hujarnis et al. (2017)                                              | • Pkd2 knock-out mouse                                                             | Cyst burden                                                             |
|             |                      | Lakhtia et al. (2018)                                               | • Pkd2fl/fl::Ksp-Cre mouse                                                        | Cyst burden, kidney function                                             |

2DG: 2-deoxy-D-glucose; cAMP: cyclic AMP; IBMX: 3-isobutyl-1-methylxanthine; MDCK: Madin-Darby canine kidney.

*Orthologous animal model.

[^1]: [Vander Heiden et al., 2009]
AMP-activated protein kinase is a potential therapeutic target in both obesity and autosomal dominant polycystic kidney disease

AMPK, an important integrator of multiple pathways, is a therapeutic target of particular interest. AMPK functions as a major molecular sensor of cellular energy, responding to energy depletion by switching on catabolic pathways and switching off anabolic pathways (Hardie et al., 2012). As summarized in a recent review, AMPK plays a central role in the pathophysiology of ADPKD by modulating multiple biological processes, including cellular proliferation, autophagy, solute transport, metabolism and mitochondrial homeostasis in the kidney, all of which are important for cystogenesis (Figure 2). (Song et al., 2020)

AMPK is a heterotrimer consisting of a catalytic α-subunit, a regulatory β-subunit, and a regulatory γ-subunit assembled in a 1:1:1 ratio (Hallows et al., 2010; Hardie et al., 2012). Subunits have multiple isoforms (α1, α2, β1, β2, γ1, γ2, and γ3), each encoded by a different gene with tissue-specific expression and activity (Steinberg and Kemp, 2009). Isoform frequency in the kidney is species-dependent; for instance, the β1 subunit is present in 93, 96, and 64% of kidneys of C57BL/6J mice, Wistar Han rats, and humans, respectively (Fraser et al., 2005; Salatto et al., 2017). AMPK is activated by rising concentrations of AMP relative to ATP. Upon binding to AMP, AMPK is phosphorylated in its catalytic loop (at residue Thr172) by one of the three upstream AMPK kinases (Figure 1): liver kinase B1 (LKB1), Ca2+/calmodulin-activated protein kinase kinase β (CaM KKβ), or Tak1 kinase (TAK1) (Steinberg and Kemp, 2009; Hallows et al., 2010; Hardie et al., 2012).

It has been suggested that AMPK signaling may be suppressed with obesity (Figure 3) (Steinberg and Kemp, 2009). AMPK activity is reduced in the heart, liver, and skeletal muscle in genetic models of rodent obesity (Barnes et al., 2002; Yu et al., 2004; Wangyun and Unger, 2005; Sriwijitkamol et al., 2006; Steinberg et al., 2006). On the other hand, AMPK activity is not always altered in the tissues of animals with HFD-induced obesity, nor is it altered in the skeletal muscle of obese humans (Steinberg and Carling, 2019).

TABLE 2 Clinical studies investigating metabolic agents of interest in the treatment of ADPKD.

| Agent       | Mechanism of action | Study                          | Evidence                                      | Advantages/Disadvantages of the therapy |
|-------------|---------------------|--------------------------------|-----------------------------------------------|----------------------------------------|
| Sirolimus   | mTOR inhibitor      | Serra et al. (2010) RCT        | Inconclusive (low number of patients, short follow-up, no difference in TKV) | • Multiple side effects                 |
|             |                     | Perico et al. (2010) RCT/T     |                                               | • Accelerated disease progression in patients with advanced CKD |
|             |                     | Braun et al. (2014) RCT        |                                               |                                        |
|             |                     | Ruggenenti et al. (2016) RCT   |                                               |                                        |
|             |                     | Ongoing trial: NCT02055079 (status unknown) |                                        |                                        |
| Everolimus  | mTOR inhibitor      | Walz et al. (2010) RCT         | Inconclusive (effect on TKV not maintained)  | • Multiple side effects                 |
| Metformin   | AMPK agonist        | Sorohan et al. (2019) SA       | Good tolerability, studies not designed to assess change in kidney function | • Well-known, inexpensive drug         |
|             |                     | Perrone et al. (2021) RCT      |                                               | • G-I side effects                     |
|             |                     | Brosnahan et al. (2022) RCT    |                                               | • Risk of lactic acidosis with lower kidney function |
|             |                     | Ongoing trials: NCT03764605 (status unknown); NCT04939995 (not yet recruiting) |                                        |                                        |

CKD: chronic kidney disease; RCT: randomized controlled trial; RCrT: randomized crossover trial; G-I: gastro-intestinal; SA: single-arm pilot study; TKV: total kidney volume.
activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) for 1 week restored AMPK activity, preventing kidney hypertrophy and macrophage infiltration (Declèves et al., 2011). However, it should be noted that AICAR has a number of AMPK-independent effects, and can lower blood pressure and blood glucose; as such, these results should be interpreted with caution. Interestingly, in a later study, HFD-induced renal injury was further described as vacuolated proximal tubular cells with loss of the brush border, suggesting tubular damage (Declèves et al., 2014). Glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide was shown to restore AMPK signaling, and reduce glomerular size, glomerulosclerosis, and interleukin levels in obese Sprague-Dawley rats (Wang et al., 2018). Therefore, obesity-related kidney disease associated with lipid deposits appears to be mediated by suppressed AMPK activity, affecting both the glomerular and tubular compartments of the kidney.

Following the initial preclinical research examining the role of mTORC1 in ADPKD, several studies focused on its inhibitor AMPK. More than 10 years ago, metformin, an AMPK agonist,
was used to suppress cystogenesis in an in vitro model, an ex vivo model, and two mouse models of ADPKD (Table 1). Metformin was shown to reduce mTOR signaling in the kidneys of the two mouse models (Takiar et al., 2011). The authors concluded that AMPK activation may alleviate cystic disease by two main mechanisms: by inhibiting the pro-proliferative mTOR pathway and the cystic fibrosis transmembrane conductance regulator (CFTR) channel that mediates fluid secretion into cysts (Takiar et al., 2011). In a subsequent study, AMPK phosphorylation was demonstrated to be reduced in fibroblasts isolated from Pkd1 knock-out mouse embryos compared to wild-type cells (Rowe et al., 2013). In addition to its inhibitory effect on mTORC1, AMPK may potentially suppress cell proliferation in cysts by phosphorylating and activating eukaryotic elongation factor 2 kinase (eEF2K), which plays an essential role in inhibiting protein synthesis (Steinberg and Kemp, 2009). The distribution of AMPK in the kidney further supports its role in cystogenesis, as phosphorylated AMPK was detected on the basolateral surface of the rat collecting duct, which in the adult kidney is a major site of cyst formation (Fraser et al., 2005; Harris and Torres, 2009).

While the molecular cause for suppressed AMPK activity in ADPKD remains unclear, Pkd1 knock-out mouse embryonic fibroblasts (MEFs) displayed increased activity of the extracellular signal-regulated kinase (ERK). In the same experiment, ERK inhibited TSC2, which may contribute to mTORC1-mediated cell proliferation (Distefano et al., 2009). Although ERK has been postulated to suppress the LKB1-AMPK axis in Pkd1 knock-out MEFs, this pathway remains to be confirmed (Rowe et al., 2013).

Pharmacological agonists of AMP-activated protein kinase show promise in the treatment of autosomal dominant polycystic kidney disease

Several drugs that activate AMPK may have applications in the treatment of ADPKD. Metformin, an oral agent commonly used to treat type 2 diabetes, activates AMPK indirectly by inhibiting complex 1 of the electron transport chain, leading to a drop in cellular ATP and an increase in AMP (Rena et al., 2017). In an in vitro model of kidney cystogenesis, metformin inhibited the expression of glycolytic genes and lowered lactate production (Riawan et al., 2016). Several animal studies have demonstrated that metformin improves cystic disease (Table 1). In two Pkd1 knock-out mouse models, metformin ameliorated cystic kidney disease (Takiar et al., 2011). Moreover, in MEFs isolated from Pkd1 knock-out embryos, phosphorylated AMPK was reduced compared to wild-type cells; treating the mutant cells with metformin or AICAR restored AMPK activity (Rowe et al., 2013). In a minipig model and a zebrafish model, metformin similarly activated AMPK, thereby reducing cyst formation (Chang et al., 2017; Lian et al., 2017; Lian et al., 2019). Importantly, metformin improved disease severity in the Pkd1 RC/RC mouse model, which approximates the slow progression of cystic disease in humans (Pastor-Soler et al., 2022). Pilot metformin studies in human populations with ADPKD did not show a benefit on eGFR, although the drug was well tolerated in both a single-arm study and two randomized controlled trials (Table 2). (Sorohan et al., 2019; Perrone et al., 2021; Brosnahan et al., 2022). Two additional trials of metformin in ADPKD are ongoing in Italy and Australia (NCT03764605 and NCT04939935, respectively).

Canagliflozin, an SGLT2 inhibitor used to treat type 2 diabetes, has the off-target effect of activating AMPK indirectly by inhibiting mitochondrial respiration (Leonhard et al., 2019). By contrast, salicylate derived from the pro-drug salsalate activates AMPK directly by binding to its β-subunit. Salsalate, unlike aspirin, interacts little with the cyclooxygenase pathway, which limits the occurrence of gastrointestinal and bleeding side effects (Anderson et al., 2014). In a collaboration between our group and Leiden University, salsalate alone or in combination with metformin was shown to decrease kidney weight and improve survival from ESKD in an adult-onset conditional Pkd1 knock-out mouse model. Conversely, treatment was ineffective with metformin alone, canagliflozin alone, or metformin in combination with canagliflozin (Leonhard et al., 2019). In this study, the method of administration of metformin was different (oral) from that used by Takiar et al. (2011) (intraperitoneal), but the dosage was identical; the relatively low oral bioavailability of metformin (~30–60%) likely limited its action in the kidneys (Padwal et al., 2011). Although the same oral metformin dosage was used in the Pkd1 RC/RC mouse study, the longer duration of treatment in the latter may explain the improvement seen in kidney disease (Pastor-Soler et al., 2022). To our knowledge, there are currently no clinical trials of salsalate in ADPKD.

Lastly, AMPK-activating resveratrol, a polyphenol that also activates sirtuin 1 (SIRT1), was used to reverse diabetic nephropathy and prevent lipid-induced nephrotoxicity in db/db mice (Kim et al., 2013). Nonetheless, because treatment with a pan-sirtuin inhibitor (nicotinamide) and a SIRT1-specific inhibitor (EX-527) delayed cyst growth in Pkd1 knock-out mouse embryonic kidneys, Pkd1 conditional knock-out postnatal mice, and Pkd1 hypomorphic mice, it is unclear whether sirtuin 1 is an interesting drug target in combined obesity and ADPKD (Zhou et al., 2013). In conclusion, AMPK-activating drugs such as metformin and salsalate are clinically easier to tolerate than mTORC1 inhibitors, making them more promising candidates to control cystogenesis in ADPKD. However, more clinical trials are needed.
AMP-activated protein kinase interacts with other processes relevant to the pathophysiology of autosomal dominant polycystic kidney disease

In addition to modulating cell proliferation and fluid secretion, AMPK regulates other processes that have been shown to be abnormal in ADPKD, such as mitochondrial structure and function, the peroxisome proliferator-activated receptor α (PPARα) pathway, and the innate immune response (Figure 2). (Song et al., 2020)

The kidney displays mitochondrial abnormalities in both obesity and autosomal dominant polycystic kidney disease

Strong evidence indicates that AMPK promotes mitochondrial biogenesis by activating peroxisome proliferator-activated receptor γ coactivator-1 α (PGC-1α) (Steinberg and Kemp, 2009). As a transcriptional coactivator, PGC1α interacts with nuclear respiratory factors 1 and 2 (NRF1 and NRF2), which regulate mitochondrial transcription factor A (TFAM), the latter playing a crucial role in maintaining mitochondrial DNA transcription and replication. (Figure 2). (Kelly and Scarpula, 2004; Reznick and Shulman, 2006)

Mitochondrial dysfunction, presumably related to insulin resistance, is present in obesity, affecting tissues that participate in nutrient metabolism such as the adipose tissue, liver, and skeletal muscle (Bournat and Brown, 2010; Montgomery and Turner, 2015). The progressive enlargement of white adipose tissue in mice and humans can impair blood flow and result in hypoxia, which can lead to macrophage recruitment and infiltration (Wood et al., 2009). In turn, inflammation, in addition to excessive food intake, may increase the production of reactive oxygen species, causing mitochondrial dysfunction, although there is also evidence the latter may in fact precede adipose tissue inflammation (Lahera et al., 2017; de Mello et al., 2018; Woo et al., 2019). Increased mitochondrial fission, defective mitochondrial biogenesis and oxidative capacity, and intracellular triglyceride overload have been described in the adipose tissue, liver, and skeletal muscle of obese rodents and humans (Bournat and Brown, 2010; de Mello et al., 2018). In the kidney specifically, mitochondrial abnormalities have been inconsistently described in ob/ob mice and mice with HFD-induced obesity (Declèves et al., 2014; Szeto et al., 2016). Liraglutide restored AMPK and PGC-1α signaling in the kidneys of HFD-fed rats, and inhibited the formation of mitochondrial reactive oxygen species (Wang et al., 2018). There is also evidence that SS-31, an antioxidant that protects the structure of mitochondrial cristae, may prevent the renal toxicity, including mitochondrial damage, caused by fatty acid accumulation (Szeto et al., 2016).

The role of mitochondria in the pathophysiology of ADPKD has been covered in depth in several recent reviews (Padovano et al., 2018; Menezes and Germino, 2019; Nowak and Hopp, 2020; Podrini et al., 2020). Briefly, mitochondrial abnormalities can be found in Pkd1 knock-out kidney epithelial cells isolated from mice, in mouse and rat models of polycystic kidney disease, and in kidney tissues from patients with ADPKD (Ishimoto et al., 2017; Lin et al., 2018). Morphological changes on electron microscopy include swelling and fragmentation of the mitochondria, and damaged cristae. These morphological changes in mitochondria, suggestive of defects in mitophagy, are very analogous to those observed in mice deficient for AMPK in muscle and brown adipose tissue (Bujak et al., 2015; Mottillo et al., 2016). Moreover, the mitochondrial DNA copy number decreases from an early stage of ADPKD, in parallel with kidney mRNA and protein expression of PGC-1α (Ishimoto et al., 2017). Several studies have highlighted that the impairment of mitochondrial metabolic processes such as fatty acid oxidation and oxidative phosphorylation drives cyst formation, in part via reduced PPARα expression (Menezes et al., 2012; Rowe et al., 2013; Menezes et al., 2016; Hajarnis et al., 2017; Padovano et al., 2017; Podrini et al., 2018). Because of defective fatty acid oxidation, a higher fat intake aggravated the kidney cyst burden in a non-orthologous rat and two orthologous mouse models of polycystic kidney disease (Jayapalan et al., 2000; Menezes et al., 2016). Since PC1 and PC2 appear to affect both the morphology and function of mitochondria, mitochondrial dysfunction might be one of the original molecular events preceding metabolic dysregulation in ADPKD (Padovano et al., 2017; Lin et al., 2018; Kuo et al., 2019).

Peroxisome proliferator-activated receptor α activation ameliorates lipid-induced toxicity in the kidney

AMPK phosphorylates, thereby activating, PGC-1α, which acts as a transcriptional coactivator of PPARα (Figure 2). (Vega et al., 2000; Steinberg and Kemp, 2009) The AMPKα subunit can also coactivate PPARα independently of its kinase activity (Bronner et al., 2004). This ligand-activated transcription factor binds to fatty acids to regulate essential metabolic responses to fasting, including ketogenesis in the liver and fatty acid utilization in multiple tissues such as the kidney (Kersten et al., 1999; Guan, 2002; Wang, 2010). In a mouse model of HFD-induced glomerular injury, treatment with the PPARα agonist fenofibrate increased the expression of lipolytic enzymes, reducing lipid accumulation and oxidative stress in the glomeruli, and preventing glomerular fibrosis (Tanaka et al., 2011). The network comprising PPARα and its gene targets is known to be downregulated in mouse models of ADPKD and human cysts, and PPARα downregulation
is in part responsible for the intrinsic defect in fatty acid oxidation seen in ADPKD (Hajarnis et al., 2017; Lakhia et al., 2018; Lakhia, 2020). One mechanism underlying PPARα downregulation may be post-transcriptional inhibition by the microRNAs miR-17–92 and miR-21, which are upregulated in mouse and human ADPKD (Lakhia et al., 2016; Hajarnis et al., 2017). Using fenofibrate improved the phenotype of both aggressive and slowly progressive mouse models of ADPKD, and ameliorated the tubulointerstitial fibrosis associated with reduced fatty acid oxidation (Table 1). (Kang et al., 2015; Hajarnis et al., 2017; Lakhia et al., 2018) However, although fibrates are commonly used in the treatment of dyslipidemia, their long-term safety in kidney disease remains unclear (Jun et al., 2012; Melissa et al., 2020).

Chronic inflammation is a feature of obesity and autosomal dominant polycystic kidney disease

Both obesity and ADPKD are associated with a state of low-grade chronic inflammation. While other immune components participate in the inflammatory phenotype in both conditions, macrophages have been most extensively studied and play a dominant role (Zimmerman et al., 2020). In obesity, the upregulation of monocyte chemoattractant protein 1 (MCP-1) in fat depots with resulting accumulation of macrophages is crucial to induce inflammation in the adipose tissue (Oh et al., 2012; Amano et al., 2014). In humans, increased circulating MCP-1 correlates with higher levels of other inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), but also obesity, waist circumference, and the homeostatic model assessment for insulin resistance (HOMA-IR) score (Kim et al., 2006). Studies in obese mice support the causal role for MCP-1-mediated macrophage accumulation in adipose tissue in promoting insulin resistance (Kamei et al., 2006; Kanda et al., 2006; Weisberg et al., 2006; Aouadi et al., 2013; Kim et al., 2016). Interestingly, macrophage AMPKβ1 appears to blunt the inflammatory response to saturated fatty acids by increasing fatty acid oxidation (Galic et al., 2011).

In patients with ADPKD, the inflammatory markers MCP-1 and macrophage migration inhibitory factor (MIF) are elevated in the urine and cyst fluid (Zheng et al., 2003; Meijer et al., 2010; Kim and Tam, 2011; Chen et al., 2015). Urinary MCP-1 correlates with TKV and predicts progression to CKD stage 3 (Meijer et al., 2010; Chapman et al., 2012; Messchendorp et al., 2018; Segarra-Medrano et al., 2020). In an inducible knock-out model of Pkd1, MCP-1 upregulation, independently of tubular injury, caused monocyte infiltration. Monocytes differentiated into pro-inflammatory M1-like macrophages that accumulated around cysts, causing oxidative damage and tubular injury; a switch to alternatively activated M2-like macrophages then coincided with increased cyst proliferation (Cassini et al., 2018). In fact, most interstitial macrophages in the kidneys of patients with ADPKD were found to be M2-like, and human cyst cells were shown to promote M2-like macrophage polarization in vitro by secreting soluble factors including lactates (Swenson-Fields et al., 2013; Yang et al., 2018). M2-like macrophages, normally involved in tissue repair, are likely locked in a maladaptive cycle of pro-proliferative and pro-fibrotic activity (Weimbs, 2018). Previous work reported that global macrophage depletion with liposomal clodronate slowed kidney disease progression in non-orthologous and orthologous mice (Karihaloo et al., 2011; Swenson-Fields et al., 2013; Yang et al., 2018). Moreover, attenuating macrophage accumulation in Pkd1-deficient mice with Mcp1 knock-out or an antagonist of the MCP-1 receptor (also known as CCR2) reduced cyst growth and tubular injury (Cassini et al., 2018; Viau et al., 2018).

Importantly, the proinflammatory cytokine MIF is associated on the one hand with increases in MCP-1, tumor necrosis factor α (TNF-α), and macrophage accumulation, and on the other hand with increased glucose uptake and glycolytic gene expression, inhibition of AMPK activity, and activation of ERK and mTOR signaling (Chen et al., 2015). Its deletion or pharmacologic inhibition has reversed these abnormalities and slowed disease progression in multiple Pkd1-deficient murine models (Chen et al., 2015). As an additional link between kidney inflammation and metabolic disease, LKB1 forms a complex with PCI to suppress the expression of MCP-1 in tubular epithelia; the tubular deletion of Lkb1 or Pkd1 restores MCP-1 expression and causes monocyte/CCR2+ macrophage recruitment (Viau et al., 2018). This is notable because ciliary LKB1 colocalizes with and activates AMPK (Boehlke et al., 2010; Mick et al., 2015). Thus, similarly to MIF, LKB1 appears to be an upstream regulator of both inflammatory and metabolic changes in ADPKD.

Conclusion

The pathobiology of ADPKD is strongly linked to metabolic dysregulation, which may be secondary to mitochondrial abnormalities induced by defective polycystin function. Pathways common to both obesity-related kidney disease and ADPKD suggest that obesity with ectopic lipid deposition in the kidneys may contribute to the progression of cystic disease through various mechanisms, notably through inhibition of AMPK activity. Overweight and obesity are frequent in patients with ADPKD, and weight loss should be beneficial for both conditions (Pickel et al., 1093; Nowak et al., 2018). Further work will be needed to understand if and how weight loss can attenuate cystogenesis on a molecular level. In addition to dietary changes, pharmacological activation of AMPK may attenuate lipid-related kidney injury as well as the cystic burden. The repurposing of metabolic drugs to treat patients with ADPKD has seen limited development thus far.
Nevertheless, based on promising in vivo data, it is reasonable to believe that well-known and relatively safe pharmacological agents such as metformin or salsalate, both of which activate AMPK, could attenuate lipid-induced nephrotoxicity and reduce cystic disease severity. Given the slow progression of human ADPKD, using pharmacological agents that are safe and tolerable will be critical.

Author contributions

I-AI wrote the different versions of the manuscript, with help from LP and guidance from XS, YP, GS, and H-KS. LP, XS, AH, JS, H-KS, GS, and YP helped to revise the manuscript. All authors approve the final version of this manuscript.

Funding

I-AI was supported by a KRESCENT fellowship (KRES170001) (Kidney Foundation of Canada) from 2017 to 2020 and holds a 2021–2022 Queen Elizabeth II/Dr. Arnie Aberman Graduate Scholarship in Science and Technology (University of Toronto).

Acknowledgments

We would like to thank Christina Beharry for helping edit parts of the manuscript. Copyright-free art from Wikimedia Commons and Open Clip Art was used to design Figure 3.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Abacar-Gomez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., et al. (2017). Worldwide trends in body mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 390 (10113), 2627–2642. doi:10.1016/S0140-6736(17)32129-3

Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Donato, K. A., et al. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention, national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120 (16), 1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644

Amano, S. U., Cohen, J. L., Vangala, P., Tencerrova, M., Nicoloro, S. M., Yawe, J. C., et al. (2014). Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell. Metab. 19 (1), 162–171. doi:10.1016/j.cmet.2013.11.017

Anderson, K., Wherle, L., Park, M., Nelson, K., and Nguyen, L. (2014). Salsalate, an old, inexpensive drug with potential new indications: A review of the evidence from 3 recent studies. Am. Health Drug Benefits 7 (4), 231–235.

Aouadi, M., Tencerrova, M., Vangala, P., Yawe, J. C., Nicoloro, S. M., Amano, S. U., et al. (2013). Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice. Proc. Natl. Acad. Sci. U. S. A. 110 (20), 8279–8283. doi:10.1073/pnas.1308492110

Baldwin, S. A., Barros, L. F., Griffiths, M., Ingram, J., Robbins, E. C., Streets, A. J., et al. (1997). Regulation of GLUT1 in response to cellular stress. Biochem. Soc. Trans. 25 (3), 954–958. doi:10.1042/bst0250954

Bandopadhyay, G. K., Yu, J. G., Ofrecio, J., and Ofeltik, M. J. (2006). Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55 (8), 2277–2285. doi:10.2337/db06-0062

Barnes, B. R., Ryder, J. W., Steiler, T. L., Fryer, L. G. D., Carling, D., and Zierath, J. R. (2002). Isoform-specific regulation of 5′ AMP-activated protein kinase in skeletal muscle from obese Zucker (fa/fa) rats in response to contrac tion. Diabetes 51 (9), 2703–2708. doi:10.2337/diabetes.51.9.2703

Barua, M., Gil, O., Paterson, A. D., Wang, K., He, N., Dicks, E., et al. (2009). Family history of renal disease severity predicts the mutated gene in ADPKD. J. Am. Soc. Nephrol. 20 (8), 1833–1838. doi:10.1681/ASN.2009020162

Boehlke, C., Konis, F., Patel, V., Braeg, S., Voelker, H., Bredt, S., et al. (2010). Primary cilia regulate mTORC1 activity and cell size through LKB1. Nat. Cell. Biol. 12 (11), 1115–1122. doi:10.1038/ncb2117

Bournat, J. C., and Brown, C. W. (2010). Mitochondrial dysfunction in obesity. Curr. Opin. Endocrinol. Diabetes Obes. 17 (5), 446–452. doi:10.1097/MED.0b013e3283c3026

Bouteuja, F., Stichem, C. M., and Platta, H. W. (2019). mTOR: A cellular regulator interface in Health and disease. Cells 8 (1), 18. doi:10.3390/cells8010018

Braun, W. E., Schold, J. D., Stephany, B. R., and Spirkos, R. A. (2014). Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: An open-label randomized controlled pilot study. Clin. J. Am. Soc. Nephrol. 9 (5), 881–888. doi:10.2215/CJN.0250313

Bronner, M., Hertz, R., and Bar-Tana, J. (2004). Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor α by AMPK-activated protein kinase. Biochem. J. 384 (2), 295–305. doi:10.1042/BJ20040955

Brosnahan, G. M., Wang, W., Gitomer, B., Streuemp, T., George, D., You, Z., et al. (2022). Metformin therapy in autosomal dominant polycystic kidney disease: A feasibility study. Am. J. Kidney Dis. 79, 518–526. doi:10.1053/j.ajkd.2021.06.026

Bujak, A. L., Cranz, J. D., Lally, J. S., Ford, R. J., Kang, S. J., Rebalka, I. A., et al. (2015). AMPK activation of muscle autophagy prevents fasting-induced hypoglycaemia and myopathy during aging. Cell. Metab. 21 (6), 883–890. doi:10.1016/j.cmet.2015.05.016

Cassini, M. F., Kakade, V. R., Kuritz, E. T., Sulkowski, P., Glazer, P., Torres, R., et al. (2018). MCP1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 29 (10), 2471–2481. doi:10.1681/ASN.2018050158

Chang, M. Y., Ma, T. L., Hung, C. C., Tian, Y. C., Chen, Y. C., Yang, C. W., et al. (2017). Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci. Rep. 7 (1), 7161. doi:10.1038/s41598-017-07300-x

Iliuta et al. 10.3389/fmolb.2022.962933

Frontiers in Molecular Biosciences frontiersin.org

Author contributions

I-AI wrote the different versions of the manuscript, with help from LP and guidance from XS, YP, GS, and H-KS. LP, XS, AH, JS, H-KS, GS, and YP helped to revise the manuscript. All authors approve the final version of this manuscript.

Funding

I-AI was supported by a KRESCENT fellowship (KRES170001) (Kidney Foundation of Canada) from 2017 to 2020 and holds a 2021–2022 Queen Elizabeth II/Dr. Arnie Aberman Graduate Scholarship in Science and Technology (University of Toronto).

Acknowledgments

We would like to thank Christina Beharry for helping edit parts of the manuscript. Copyright-free art from Wikimedia Commons and Open Clip Art was used to design Figure 3.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Chapman, A. B., Bost, J. E., Torres, V. E., Guay-Woodford, L., Bae, K. T., Landtquist, D., et al. (2012). Kidney volume and functional Outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7 (3), 479–486. doi:10.2215/CJN.09500911

Chen, L., Zhou, X., Fan, L. X., Yao, Y., Swenson-Fields, K. I., Gadjieva, M., et al. (2015). Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J. Clin. Investig. 125 (6), 2399–2412. doi:10.1172/JCI8467

Chiaravalli, M., Rowe, I., Mannella, V., Quilici, G., Canu, T., Bianchi, V., et al. (2016). 2-Deoxy-Glucone ameliorate PKD progression. J. Am. Soc. Nephrol. 27 (7), 1958–1969. doi:10.1681/ASN.2015030321

Corne-Le Gall, E., Audrèzet, M. P., Chen, J. M., Hourmant, M., Morin, M. P., Perrichot, R., et al. (2013). Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol. 24 (6), 1006–1013. doi:10.1681/ASN.2012070656

de Mello, A. H. Costa, A. B., Engel, J. D. G., and Reinz, G. T. (2018). Mitochondrial dysfunction in obesity. Life Sci. 192, 26–32. doi:10.1016/j.lfs.2017.11.019

Declèves, A. E., Mathew, A. V., Cunard, R., and Sharma, K. (2011). AMPK mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc. Nephrol. 22 (10), 1846–1855. doi:10.1681/ASN.2011010026

Declèves, A. E., Zolkipli, Z., Satriono, J., Wang, L., Nakayama, T., Rogac, M., et al. (2014). Regulation of lipid accumulation by AMP-activated kinase [corrected] in renal physiology and its downstream effectors S6K and 4EBP1. J. Am. Soc. Nephrol. 29 (9), 2359–2371. doi:10.1681/ASN.2012120259-008

Fall, T., Mendelson, M., and Speliotes, E. K. (2013). Recent advances in human genetics and epigenetics of adiposity: Pathway to precision medicine? Front. Physiol. 4, 11. doi:10.3389/fphys.2013.00154

Franks, S., Mount, P., Hill, R., Levidiotis, K., Zaffis, F., Stapleton, D., et al. (2005). Regulation of the energy sensor AMP-activated protein kinase in the kidney by dietary salt intake and osmolality. Am. J. Physiol. Ren. Physiol. 288 (3), F578–F586. doi:10.1152/ajprenal.00190.2004

Gadde, K. M., Martin, C. K., Berthoud, H. R., and Heysmiful, S. B. (2018). Obesity: Pathphysiology and Management. Obs. J. Am. Coll. Cardiol. 71 (1), 69–84. doi:10.1016/j.jacc.2017.11.011

Gallic, S., Fullerton, M. D., Schertzer, J. D., Sikkema, S., Marcinko, K., Walkley, C. R., et al. (2011). Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage infiltration and insulin resistance in obesity. J. Clin. Investig. 121 (12), 4903–4915. doi:10.1172/JCI58577

Grant, J. (2008). Clinical practice. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 359, 1477–1485. doi:10.1056/NEJMcp0804455

Guan, Y. (2002). Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Minerva Urol. Nefrol. 54 (2), 65–79.

Hajarsim, S., Lakha, R., Yheshk, M., Williams, D., Sorourian, M., Liu, X., et al. (2017). microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat. Commun. 8 (1), 14395. doi:10.1038/ncomms14395

Halowes, K. R., Mount, P. F., Pastor-Soler, N. M., and Power, D. A. (2010). Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am. J. Physiol. Ren. Physiol. 298 (5), F1067–F1077. doi:10.1152/ajprenal.00152.2010

Hardt, D. G., Ross, F. A., and Hawley, S. A. (2012). AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell. Biol. 13 (4), 251–262. doi:10.1038/nrm3311

Harris, P. C., and Torres, V. E. (2009). Polycystic kidney disease. Annu. Rev. Med. 60, 321–337. doi:10.1146/annurev.med.60.100707.123712

Haumann, S., Möller, R. U., and Liebau, M. C. (2020). Metabolic changes in polycystic kidney disease as a potential target for systemic treatment. Int. J. Mol. Sci. 21 (17), 6693. doi:10.3390/ijms21176693

Heyer, C. M., Sundsbak, J. L., Abebe, K. Z., Chapman, A. B., Torres, V. E., Granham, J. J., et al. (2016). Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27 (9), 2872–2884. doi:10.1681/ASN.2015050583

Hwang, Y. H., Conklin, J., Chan, W., Roslin, N. M., Liu, J., He, N., et al. (2016). Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27 (6), 1861–1868. doi:10.1681/ASN.2015060648
Laplante, M., and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell. 149 (2), 274–293. doi:10.1016/j.cell.2012.03.017

Lee, E. J., See, E., Kim, J. W., Nam, S. A., Lee, J. Y., Jun, J., et al. (2020). TAZ/Wt1-specific ABCA1-MYC axis regulates cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 117 (46), 29001–29012. doi:10.1073/pnas.2009933117

Leonhard, W. N., Song, X., Kanhai, A. A., Illuta, I. A., Bozovic, A., Steinberg, G. R., et al. (2019). Salutare, but not metformin or canagliflozin, slows kidney cyst growth in an adult mouse model of polycystic kidney disease. Elife 47, 436–445. doi:10.7554/e9.2019.09.041

Lian, X., Wu, X., Li, Z., Zhang, Y., Song, K., Cai, G., et al. (2019). The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br. J. Pharmacol. 176 (5), 711–724. doi:10.1111/bph.14558

Lian, X., Zhao, J., Wu, X., Zhang, Y., Li, Q., Lin, S., et al. (2017). The changes in glucose metabolism and cell proliferation in the kidneys of polycystic kidney disease mini-pig models. Biochem. Biophys. Res. Commun. 488 (2), 374–381. doi:10.1016/bibs.2017.05.060

Lin, C. C., Kurashige, M., Liu, Y., Terabayashi, T., Ishimoto, Y., Wang, T., et al. (2018). A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. J. Biol. Chem. 283 (28), 18933–18941. doi:10.1074/jbc.M118312002

Meijer, E., Boer, R. W., Eeftinck Schattenkerk, J. C., van der Walt, H. P., Houwing-Duistermaat, J. J., et al. (2011). Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 34 (6), 1295–1300. doi:10.2337/dc10-2140

Rezvani, R. S., Babo, R. O., Sharma, A. M., Langkaas, L. A., Birch, D. W., Karim, S., et al. (2011). Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 34 (6), 1295–1300. doi:10.2337/dc10-2140

Ricard-Blum, S., Audrel, D., Belo, S., Borel, E., Boudreau, E., et al. (2016). Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am. J. Physiol. Ren. Physiol. 322 (1), F27–F41. doi:10.1152/ajprenal.00028.2018

Radin, M., Antiga, L., Caroli, A., Raggenbenti, P., Fasolino, G., Cafaro, M., et al. (2010). Sirolimus therapy to halt the progression of ADPKD. J. Am. Soc. Nephrol. 21 (11), 1831–1834. doi:10.1681/ASN.2010040345

Salsalate, but not metformin or canagliflozin signifi-

Salsalate, but not metformin or canagliflozin significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br. J. Pharmacol. 176 (5), 711–724. doi:10.1111/bph.14558

Salsalate, but not metformin or canagliflozin significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br. J. Pharmacol. 176 (5), 711–724. doi:10.1111/bph.14558
dominant polycystic kidney disease and CKD stages 3b–4. Clin. J. Am. Soc. Nephrol. 11 (5), 785–794. doi:10.2215/CJN.09900915
Salatto, C. T., Miller, R. A., Cameron, K. O., Cokroitos, E., Reyes, A., Ward, J., et al. (2017). Selective activation of AMPK β1-containing isoforms improves kidney function in a rat model of diabetic nephropathy. J. Pharmacol. Exp. Ther. 361 (2), 303–311. doi:10.1124/jpet.123.273925
Scherer, R. W., McFann, K. K., and Johnson, A. M. (2003). Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 63 (2), 678–685. doi:10.1016/S1523-1755(03)00776-X
Segarra-Medrano, A., Martin, M., Agrat, I., Vilaplana, M., Chamoun, B., Jatem, E., et al. (2020). Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease. Clin. Kidney J. 13, 607–612. doi:10.1093/ckj/sfx105
Serra, A. L., Foster, D., Kisler, A. D., Krauer, F., Raina, S., Young, J., et al. (2010). Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363 (9), 820–829. doi:10.1056/NEJMoa0907419
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., et al. (2006). The mTOR pathway is regulated by p53-dependent, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 103 (14), 5466–5471. doi:10.1073/pnas.0509694103
Shillingford, J. M., Piontek, B. K., Germino, G. G., and Weimbs, T. (2010). Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 21 (5), 489–497. doi:10.1681/ASN.2009040421
Song, X., Tsakiridis, E., Steinberg, G. R., and Pei, Y. (2020). Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. Cell. Signal. 73, 109704. doi:10.1016/j.cellsig.2020.109704
Sorohan, B. M., Ismail, G., Andronesi, A., Micu, G., Obri, E., et al. (2020). Selective activation of AMPK α1 and AMPK α2 inhibits AMPK activity and phosphorylates AMPK Ser473 through Akt in hepatocytes, myotubes and incubated rat skeletal muscle. Arch. Biochem. Biophys. 562, 62–69. doi:10.1016/j.abb.2014.08.013
van Herpen, N. A., and Schrauwen-Hinderling, V. B. (2008). Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol. Behav. 94 (2), 231–241. doi:10.1016/j.physbeh.2007.11.049
Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324 (5930), 1029–1033. doi:10.1126/science.1160809
Vega, R. B., Huss, J. M., and Kelly, D. P. (2000). The coactivator PGC-1 cooperates with peroxisome proliferator-activator receptor a in a transcrptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20 (5), 1868–1876. doi:10.1128/MCB.20.5.1868-1876.2000
Viau, A., Bienaimé, F., Lukas, K., Todkar, A. P., Knoll, M., Yakulov, T. A., et al. (2018). Cilia-localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney. EMBO J. 37 (15), e96155. doi:10.15252/embj.201798615
Wahl, P. R., Serra, A. L., Le Hir, M., Mollé, K. D., Hall, M. N., and Wüthrich, R. P. (2006). Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transplant. 21 (5), 594–603. doi:10.1093/ndt/gfl181
Walz, G., Budde, K., Mannava, M., Nurnberger, J., Wagner, C., Sommerer, C., et al. (2010). Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363 (9), 830–840. doi:10.1056/NEJMoa1003941
Wang, C., Li, L., and Liu, S. (2018). “GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis.”. Editor. J. A. Joles, Elsevier 1913473. doi:10.1371/journal.pone.0194373
Wang, Y. X. (2010). PPARs: Diverse regulators in energy metabolism and metabolic diseases. Cell. Res. 20 (2), 124–137. doi:10.1038/cr.2010.13
Wangyun, M., and Unger, R. H. (2003). Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. Am. J. Physiol. Endocrinol. Metab. 290 (5), E825–E832. doi:10.1152/ajpendo.00249.2005
Weinberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., et al. (2006). CCR2 modulates inflammation and metabolic effects of high-fat feeding. J. Clin. Invest. 116 (1), 115–124. doi:10.1172/JCI24355
Weisberg, S. P., Rizza, R. A., and Shulman, G. I. (2008). Adipose tissue biology. Nature 457 (7229), 389–395. doi:10.1038/nature07730
Woo, C. Y., Jang, J. E., Lee, S. E., Koh, E. H., and Lee, K. U. (2019). Mitochondrial dysfunction in adipocytes as a primary cause of adipose tissue dysfunction. Diabetes Metab. J. 43 (3), 247–256. doi:10.9733/dmj.2018.0221
Wood, I. S., de Heredia, F. P., Wang, B., and Traylor, P. (2009). Cellular hypoxia and adipose tissue dysfunction in obesity: Symposium on ‘Frontiers in adipose tissue biology. Proc. Nutr. Soc. 68 (4), 370–377. doi:10.1017/S0029665109990206
Wu, M., Wahl, P. R., Le Hir, M., Wackerle-Men, Y., Wurthrich, R. P., and Serra, A. L. (2007). Everolimus retards cyst growth and preserves function in a rodent model for polycystic kidney disease. Kidney Blood Press. Res. 30 (4), 253–259. doi:10.1586/1687547708023202
Yang, Y., Chen, M., Zhou, J., Lv, J., Song, S., Fu, L., et al. (2018). Interactions between macrophages and cyst-lining epithelial cells promote kidney cyst growth in pkd1-deficient mice. J. Am. Soc. Nephrol. 29 (9), 2310–2325. doi:10.1681/ASN.2018010074
Yoon, M. S. (2017). The role of mammalian target of rapamycin (mTOR) in insulin signaling. *Nutrients* 9 (11), 1176. doi:10.3390/nu9111176

Yu, X., McCorkle, S., Wang, M., Lee, Y., Lu, J., Saha, A. K., et al. (2004). Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats. Prevention of diabetes and ectopic lipid deposition. *Diabetologia* 47 (11), 2012–2021. doi:10.1007/s00125-004-1570-9

Zafar, I., Belibi, F. A., He, Z., and Edelstein, C. L. (2009). Long-term rapamycin therapy in the Han.SPRD rat model of polycystic kidney disease (PKD). *Nephrol. Dial. Transplant.* 24 (8), 2349–2353. doi:10.1093/ndt/glp129

Zafar, I., Ravichandran, K., Belibi, F. A., Doctor, R. B., and Edelstein, C. L. (2010). Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. *Kidney Int.* 78 (8), 754–761. doi:10.1038/ki.2010.250

Zhao, P., Wong, K., Reilly, S. M., Uhmu, M., Liao, Z., Sun, X., et al. (2018). TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. *Cell. 172* (4), 731–743.e12. e12. doi:10.1016/j.cell.2018.01.007

Zheng, B., Jeong, J. H., Asara, J. M., Yuan, Y. Y., Grantor, S. R., Chin, L., et al. (2009). Oncogenic B-raf negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. *Mol. Cell.* 33 (2), 237–247. doi:10.1016/j.molcel.2008.12.026

Zheng, D., Wolfe, M., Cowley, B. D., Wallace, D. P., Yamaguchi, T., and Grantham, J. J. (2003). Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. *J. Am. Soc. Nephrol.* 14 (10), 2588–2595. doi:10.1097/01.ASN.0000088720.61783.19

Zhou, X., Fan, L. X., Sweeney, W. E., Denu, J. M., Avner, E. D., and Li, X. (2013). Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. *J. Clin. Investig.* 123 (7), 3084–3098. doi:10.1172/JCI64401

Zimmerman, K. A., Hopp, K., and Mrug, M. (2020). Role of chemokines, innate and adaptive immunity. *Cell. Signal.* 73, 109647. doi:10.1016/j.cellsig.2020.109647